Overview
- Construction at the Monksland, Athlone facility has begun, with upgrades and a new tabletting line slated to complete in phases from late 2027 through 2028.
- The expansion will add capacity for oral GLP-1 medicines, including the tablet form of Wegovy intended for non-U.S. markets.
- Novo reports rapid U.S. uptake of oral Wegovy, with about 246,000 patients by mid-February, reinforcing plans to scale global tablet production.
- The company projects up to 500 construction jobs at the 45-acre site, though some reporting cites up to 600 roles.
- The Wegovy pill is under EMA review with potential European approval expected by year-end, a development seen as important to competition with Eli Lilly.